Biocardia Historical Financial Ratios
| BCDA Stock | USD 2.27 0.06 2.58% |
Biocardia is presently reporting on over 99 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.27, Days Sales Outstanding of 45.8 or Invested Capital of 0.0 will help investors to properly organize and evaluate Biocardia financial condition quickly.
Biocardia |
About Biocardia Financial Ratios Analysis
BiocardiaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Biocardia investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Biocardia financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Biocardia history.
Biocardia Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Biocardia stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Biocardia sales, a figure that is much harder to manipulate than other Biocardia multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Biocardia dividend as a percentage of Biocardia stock price. Biocardia dividend yield is a measure of Biocardia stock productivity, which can be interpreted as interest rate earned on an Biocardia investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Most ratios from Biocardia's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Biocardia current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.At present, Biocardia's Stock Based Compensation To Revenue is projected to slightly grow based on the last few years of reporting. The current year's ROIC is expected to grow to 9.63, whereas Price To Sales Ratio is forecasted to decline to 28.01.
| 2023 | 2024 (projected) | Dividend Yield | 0.3 | 0.27 | Price To Sales Ratio | 29.48 | 28.01 |
Biocardia fundamentals Correlations
Click cells to compare fundamentals
Biocardia Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biocardia fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 29.26 | 241.45 | 32.34 | 27.39 | 29.48 | 28.01 | |
| Ptb Ratio | 8.76 | 1.83 | 3.16 | 7.57 | (8.77) | (9.21) | |
| Days Sales Outstanding | 75.57 | 2.1K | 52.86 | 54.26 | 48.21 | 45.8 | |
| Book Value Per Share | 6.3 | 28.43 | 9.2 | 4.14 | (1.14) | (1.08) | |
| Free Cash Flow Yield | (0.46) | (0.35) | (0.32) | (0.29) | (0.71) | (0.75) | |
| Operating Cash Flow Per Share | (25.1) | (18.32) | (9.19) | (8.94) | (7.06) | (7.42) | |
| Stock Based Compensation To Revenue | 4.44 | 3.83 | 20.36 | 0.88 | 2.16 | 2.4 | |
| Capex To Depreciation | 0.75 | 1.32 | 0.47 | 1.93 | 0.85 | 0.14 | |
| Pb Ratio | 8.76 | 1.83 | 3.16 | 7.57 | (8.77) | (9.21) | |
| Ev To Sales | 23.0 | 98.05 | 21.49 | 23.15 | 29.93 | 28.43 | |
| Free Cash Flow Per Share | (25.49) | (18.37) | (9.29) | (9.0) | (7.07) | (7.43) | |
| Roic | (4.94) | (0.78) | (1.19) | (2.29) | 9.17 | 9.63 | |
| Inventory Turnover | 3.67 | 89.5 | (0.004706) | (59.21) | (68.09) | (64.69) | |
| Net Income Per Share | (39.38) | (22.24) | (11.19) | (10.08) | (8.19) | (8.6) | |
| Days Of Inventory On Hand | 4.08 | (77.6K) | 5.7E-4 | (6.16) | (7.09) | (7.44) | |
| Payables Turnover | 0.39 | 0.005362 | 1.26 | 17.42 | 8.68 | 13.27 | |
| Research And Ddevelopement To Revenue | 12.06 | 67.65 | 8.43 | 6.53 | 16.2 | 11.51 | |
| Capex To Revenue | 0.11 | 0.21 | 0.22 | 0.0518 | 0.0252 | 0.0239 | |
| Cash Per Share | 14.84 | 31.73 | 11.41 | 6.23 | 0.78 | 0.74 | |
| Pocfratio | (2.2) | (2.83) | (3.17) | (3.51) | (1.41) | (1.34) | |
| Capex To Operating Cash Flow | (0.0155) | (0.00259) | (0.0112) | (0.006628) | (0.001203) | (0.001263) | |
| Pfcf Ratio | (2.17) | (2.83) | (3.13) | (3.48) | (1.41) | (1.34) | |
| Days Payables Outstanding | 931.87 | 68.1K | 289.15 | 20.95 | 42.05 | 39.94 | |
| Income Quality | 0.79 | 0.64 | 0.82 | 0.89 | 0.86 | 1.08 | |
| Roe | (6.25) | (0.78) | (1.22) | (2.44) | 7.22 | 7.58 | |
| Ev To Operating Cash Flow | (1.73) | (1.15) | (2.1) | (2.96) | (1.43) | (1.36) | |
| Pe Ratio | (1.4) | (2.33) | (2.6) | (3.11) | (1.22) | (1.15) | |
| Return On Tangible Assets | (1.93) | (0.64) | (0.8) | (1.22) | (3.87) | (3.68) | |
| Ev To Free Cash Flow | (1.7) | (1.15) | (2.08) | (2.94) | (1.43) | (1.36) | |
| Earnings Yield | (0.71) | (0.43) | (0.38) | (0.32) | (0.82) | (0.78) | |
| Net Debt To E B I T D A | 0.32 | 1.44 | 0.88 | 0.48 | (0.0183) | (0.0193) | |
| Current Ratio | 1.59 | 5.33 | 3.63 | 2.19 | 0.4 | 0.38 | |
| Tangible Book Value Per Share | 6.3 | 28.43 | 9.2 | 4.14 | (1.14) | (1.08) | |
| Receivables Turnover | 4.83 | 0.17 | 6.9 | 6.73 | 7.57 | 7.67 | |
| Graham Number | 74.71 | 119.28 | 48.13 | 30.65 | 14.47 | 13.74 | |
| Shareholders Equity Per Share | 6.3 | 28.43 | 9.2 | 4.14 | (1.14) | (1.08) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biocardia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biocardia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocardia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocardia Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.03) | Revenue Per Share 0.264 | Quarterly Revenue Growth (0.93) | Return On Assets (1.16) | Return On Equity (7.04) |
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biocardia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.